⚡ This is your brand? Claim your page FREE and bring it to life on AI search.

SKYSONA™ (elivaldogene autotemcel)

Name: SKYSONA™ (elivaldogene autotemcel) - AI Visibility Score
Creator: Engagemii
Published: 2026-06-27T23:32:59.422Z
License: https://creativecommons.org/licenses/by/4.0/

Unclaimed

AEO Score: 5/10

Monitoring for AI engine activity

In the Engagemii AEO index

skysona.com

What this score means

Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. SKYSONA™ (elivaldogene autotemcel) just got measured.

5/10 means SKYSONA™ (elivaldogene autotemcel) is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.

About SKYSONA™ (elivaldogene autotemcel)

Learn about SKYSONA, a gene therapy for boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Please see Important Safety Information, full Prescribing Information, including Boxed WARNING and Medication Guide.

Key Topics

SKYSONA™ TREATS EARLY, ACTIVE CEREBRAL ALD { "@context": "http://schema.org", "@type": "Drug", "name": "SKYSONA™ (elivaldogene autotemcel)", "description": "SKYSONA is a gene therapy for boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Please see Important Safety Information, full Prescribing Information, including Boxed WARNING and Medication Guide.", "url": "https://www.skysona.com", "activeIngredient": "elivaldogene autotemcel", "administrationRoute": "Intravenous", "dosageForm": "IV infusion", "isAvailableGenerically": false, "legalStatus": "Prescription", "manufacturer": "Genetix Biotherapeutics", "mechanismOfAction": "SKYSONA adds functional copies of the ABCD1 cDNA into patients’ hematopoietic stem cells (HSCs) through transduction of autologous CD34+ cells with Lenti-D LVV. After SKYSONA infusion, transduced CD34+ HSCs engraft in the bone marrow and differentiate into various cell types, including monocytes (CD14+) capable of producing functional ALDP. Functional ALDP can then participate in the local degradation of very long chain fatty acids (VLCFAs), which is believed to slow or possibly prevent further inflammation and demyelination.", "prescribingInfo": "https://www.genetixbiotx.com/-/media/bluebirdbio/Corporate%20COM/Files/SKYSONA/SKYSONA_prescribing_information.pdf", "medicineSystem": "Gene therapy", "audience": "Boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)", "logo": { "@type": "ImageObject", "url": "https://www.skysona.com/-/media/Skysona/com/skysona-launch/skysona-logo.svg", "caption": "SKYSONA logo" } }

How does SKYSONA work?